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Abbreviations: 
CO- Cardiac output 
ET- Exercise training 
HF – Heart failure 
HFpEF – Heart failure preserved ejection fraction 
HFrEF – Heart failure reduced ejection fraction 
HIIT – High intensity interval training 
IMT- Inspiratory muscle training 
LSHD- Left-sided heart disease 
LV – Left ventricle or ventricular 
NMES- Neuromuscular electrical stimulation 
PAP – Pulmonary artery pressure 
PH – Pulmonary hypertension 
QoL- Quality of life 
RV – Right ventricle or ventricular 
VO2 – Oxygen consumption  
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Abstract 
Pulmonary hypertension (PH) due to left-sided heart disease (LSHD) is a common and 
disconcerting occurrence.  For example, both heart failure (HF) with preserved and reduced 
ejection fraction (HFpEF and HFrEF) often lead to PH as a consequence of a chronic elevation in 
left atrial filling pressure.  A wealth of literature demonstrates the value of exercise training (ET) 
in patients with LSHD, which is particularly robust in patients with HFrEF and growing in 
patients with HFpEF.  While the effects of ET have not been specifically explored in the LSHD – 
PH phenotype (i.e., composite pathophysiologic characteristics of patient’s in this advanced 
disease state), the overall body of evidence supports clinical application in this subgroup.  
Moderate intensity aerobic ET significantly improves peak oxygen consumption, quality of life 
and prognosis in patients with HF.  Resistance ET significantly improves muscle strength and 
endurance in patients with HF, which further enhance functional capacity.  When warranted, 
inspiratory muscle training and neuromuscular electrical stimulation are becoming recognized as 
important components of a comprehensive rehabilitation program. This review will provide a 
detailed account of ET programing considerations in patients with LSHD with a particular focus 
on those concomitantly diagnosed with PH. 
Key words: Aerobic exercise; resistance exercise; inspiratory muscle training; functional 
capacity;Pulmonary Hypertension 
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 Pulmonary hypertension (PH) due to left-sided heart disease (LSHD) is a disconcerting 
occurrence with important clinical implications.
1, 2
  Heart failure (HF), mitral/aortic valvular 
disease and hypertrophic cardiomyopathy are three prime examples of LSHD that may lead to 
PH.  The manifestation of PH with LSHD is a clear indication of advanced disease severity with 
poor prognosis.  Of the three aforementioned conditions, HF has the highest profile given the 
high incidence (United States: >850,000 new cases per year) and prevalence (United States: >5.5 
million patients currently diagnosed) of this condition.
3
  Both HF with reduced and preserved 
ejection fraction (HFrEF and HFpEF) can lead to PH as a consequence of a chronic elevation in 
left atrial  filling pressure.  In fact, PH in patients with HF is a common occurrence that coincides 
with disease progression, with an estimated prevalence of ~60% in the HF population (HFrEF 
and HFpEF combined).
4
 
 Exercise training (ET) is now widely accepted as an important medical intervention (i.e., 
exercise is medicine).
5
  There is a wealth of literature demonstrating the value of ET in patients 
with LSHD; the body of evidence is particularly robust in patients with HFrEF and quickly 
growing in patients with HFpEF.
6-10
  The research conducted in this area allows us to understand 
a number of facets associated with ET in HF, including: 1) a host of expected positive 
physiologic adaptations; 2) expected clinical improvements; and 3) improvements in prognosis.  
In addition, research conducted in this area also allows for clear clinical guidance on approaches 
to ET prescription (i.e., frequency, intensity, type and time). Even so, there are clear knowledge 
gaps where additional research is needed. 
 The current review describes the mechanisms for exercise intolerance as well as ET 
considerations in patients with LSHD, particularly within the context of associated PH.  This 
review focuses on the HF model, given the current incidence and prevalence of this condition, as 
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well as the high risk of developing PH once this diagnosis is established. Clinically relevant 
guidance on approaches to ET in patients with LSHD are provided as well as recommendations 
for future research in this area.  
Pathophysiologic Mechanisms of Exercise Intolerance in LSHD 
 The augmentation of left-sided cardiac output (CO) during physical exertion is the 
primary determinant of variation in aerobic capacity from one individual to another, as described 
by the Fick equation.
11-14
 As such, the primary pathology of LSHD, left ventricular (LV) 
dysfunction that results in reduced CO, is a central explanatory factor for the diminished aerobic 
capacity that is observed in this patient population.  This is a commonality shared amongst all 
left-sided conditions: 1) HFrEF and HFpEF; 2) Mitral/Aortic valve disease/dysfunction; and 3) 
hypertrophic cardiomyopathy.  Moreover, as the severity of the LSHD worsens, CO and, 
therefore, aerobic capacity falls in parallel.  Clinically significant LSHD, past the initial mild 
stages, makes attainment of a normal age- and sex-predicted aerobic capacity virtually 
impossible. 
 The development of PH in patients with LSHD may further exacerbate the decline in left-
sided CO by: 1) decreasing transmission of blood flow from pulmonary circulation to the LV as 
a function of increasing pulmonary artery pressure (PAP); 2) a potential leftward shift of the 
septal wall induced by an increasing PAP that impacts LV filling; and 3) chronic  damage to the 
alveolar-capillary interface, impacting gas exchange.
1, 15
  This is a function of a multifactorial 
deleterious impact on pulmonary gas exchange and LV  CO during exertion.   
 The pathophysiologic milieu that significantly impacts diminished aerobic capacity in 
LSHD extends beyond the central cardiopulmonary circuit; these alterations have been 
thoroughly examined in the HF model.  Specific detrimental effects are as follows: 1) The 
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vasodilatory capacity of the peripheral vasculature is diminished, impacting availability of 
oxygenated blood for aerobic energy metabolism in working skeletal muscle; 2) Skeletal muscle 
function is altered, with diminished aerobic energy production (i.e., decreased mitochondrial 
capacity) as well as muscular strength and endurance (i.e., muscle fiber atrophy and diminished 
muscle mass); and 3) The presence of respiratory muscle weakness, resulting in the onset of 
respiratory muscle fatigue and dyspnea during aerobic exercise.
8, 16, 17
  These detrimental changes 
to the peripheral vasculature, skeletal muscle and respiratory muscle systems combine with 
cardiopulmonary pathophysiology to meaningfully impact functional capacity in patients with 
LSHD, often to profound levels.   
The detrimental impact of the LSHD process on the physiologic systems highlighted in 
this section is well characterized in the HF model, a common cause of group 2 PH
4
 that denotes 
an advanced stage.  Thus, the collective physiologic derangements described in this section are 
more likely to be present and highly evolved in patients with a LSHD – PH phenotype, which 
has been eloquently described in those diagnosed with HF.
1, 4, 18
  Moreover, patients with LSHD 
and concomitant PH commonly demonstrate a very poor tolerance to physical exertion.   
The Physiologic Effect of ET in Patients with LSHD 
 Indeed, ET portends a host of physiologic benefits in virtually all individuals across the 
continuum of care, from primordial prevention in the community to secondary prevention in 
those diagnosed with a chronic disease, the latter includes those patients diagnosed with LSHD.
11
  
Certain physiologic benefits of ET are well documented in the HF model
16
; most of this work has 
been done in patients with HFrEF although research in this area is rapidly expanding in the 
HFpEF model. 
Moderate Intensity Aerobic ET 
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The ET intervention most frequently examined in the literature is moderate intensity 
aerobic ET that spans several weeks to months.  The mode of ET is commonly a treadmill, lower 
extremity ergometer, walking program, or a combination thereof;  ET durations in these studies 
typically range from 30 to 60 minutes per session, 3-5 days per week.   
 Most evidence indicates LV systolic function (i.e., CO) does not seem to meaningfully 
improve with moderate intensity ET.
8, 19, 20
  There is some evidence to suggest an improvement 
in diastolic function following ET, although results are mixed in patients with both HFrEF
6, 8, 21
 
and HFpEF
7, 22, 23
.  With respect to other LSHD associated with PH, there is limited analysis on 
the effect of moderate intensity ET on cardiac function; a recent review called for this type of 
research in patients with hypertrophic cardiomyopathy.
24
 
 Peripherally, the documented physiologic adaptations associated with moderate intensity 
aerobic ET are much clearer; this again has been extensively studied in the HF model, 
particularly those with HFrEF.
8, 16, 17, 25
  There is a clear improvement in skeletal muscle 
characteristics, favoring an improvement in aerobic energy metabolism.  There is also strong 
evidence to indicate an improvement in peripheral vascular function, specifically an enhanced 
endothelial function and vasodilatory capacity in patients with HFrEF. The improvement in 
endothelial function in patients with HFpEF is less clear.
26
 
 Patients with HF develop unfavorable autonomic nervous system characteristics and have 
elevated systemic inflammation, the latter of which demonstrated by several markers including 
tumor necrosis factor and interleukin-6.  These alterations contribute to the downward spiral in 
physiologic systems vital to exercise performance (i.e., cardiac, vascular and skeletal muscle 
function).  Moderate intensity aerobic ET significantly increases vagal tone and reduces systemic 
inflammation in patients with HF.
8, 19
  These favorable adaptations induced by ET have clear 
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benefits to preserving/improving function of the physiologic systems that dictate aerobic exercise 
performance.   
Aerobic High Intensity Interval ET ( HIIT) 
 There has been a growing interest in aerobic HIIT in patients with HF.
27-32
  This approach 
entails 30 second to 4 minute cycles of ET at near maximal aerobic capacity [i.e., 90% of peak 
oxygen consumption (VO2) or maximal heart rate] interspersed with cycles at a substantially 
lower intensity ET(i.e., complete rest to 50% of aerobic capacity).  A clear consensus on the 
optimal HIIT training model has yet to be elucidated, although longer on/off cycles (e.g., 3 
minute on - 3 minute off) is more frequently employed. From a physiologic perspective, the most 
compelling evidence for utilization of this approach is the documented improvements in LV 
remodeling and function (i.e., CO).
30
  The majority of evidence demonstrating superior central 
adaptations with HIIT compared to moderate intensity aerobic ET has been performed in HFrEF 
cohorts.  There is initial evidence to indicate HIIT also produces enhanced improvements in left-
sided diastolic function in patients with HFpEF.
27
  Improvements in vascular and skeletal muscle 
function may also be superior following HIIT compared to moderate intensity ET.
30
  However, 
while evidence continues to mount, HIIT still requires further exploration before definitive 
clinical recommendations regarding its utility can be made; trials are ongoing to further 
determine the clinical applicability of HIIT in patients with LSHD, specifically those diagnosed 
with HF.
28
 
Resistance ET 
 Resistance ET in HF, typically in the form of moderate intensity (i.e., 50% of 1 
repetition maximum), high repetition (i.e., 10-12 repetitions), multi-joint exercises, significantly 
improves muscle mass and muscle fiber contractile properties in patients with HF, resulting in 
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improvements in both force production and endurance.
17, 33, 34
 Resistance ET also appears to 
significantly improve endothelial function.  Moreover, there appears to be no detrimental effects 
to cardiac function in HF patients who participate in moderate intensity resistance ET.
34
 
Inspiratory Muscle Training 
 Inspiratory muscle training (IMT), performed 3-7 days per week, 15-30 minutes per 
session, at 30-60% of mean inspiratory pressure, improves respiratory muscle dysfunction 
induced by HF, increasing both the force production and endurance of this system; this has 
primarily been studied in cohorts with HFrEF.
35
  There is also an ―unloading‖ of the respiratory 
musculature through IMT, which improves peripheral blood flow to exercising skeletal 
muscle.
36, 37
  In addition, IMT has demonstrated numerous additional positive adaptations in an 
animal model including: 1) reduced LV diastolic pressure; 2) increased LV systolic pressure; 3) 
decreased right ventricular (RV) hypertrophy; and 4) vagal tone.
38
 
Neuromuscular Electrical Stimulation 
 Neuromuscular electrical stimulation (NMES) delivers rhythmic electrical impulses to 
several large muscle groups that is sufficient to induce a muscle contraction; the magnitude of 
the stimulus delivered is to patient tolerance.  The muscle groups most frequently undergoing an 
NMES intervention in previous studies are the quadriceps, calves, and hamstrings. A NMES 
program increases skeletal muscle mass as well as the aerobic and contractile properties of 
individual fibers.
17, 39
  In addition, endothelial function
40
 is improved and systemic 
inflammation
41
 is reduced following an NMES intervention.  The physiologic improvements 
appear to be greatest in those patients with advanced HF severity.
42
  Recent guidelines endorse 
the use of NMES in HF patients with severe functional deficits.
43
 
Does ET Impact PH in LSHD? 
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 The impact of ET on pulmonary hemodynamics in the LSHD– PH phenotype has not 
been investigated.  Our group recently published a review on the effect of ET on PH from 
mechanisms other than LSHD; both animal and human models were assessed.
44
  The ET 
interventions in these studies were either combined aerobic, resistance and respiratory training 
interventions (7 human studies) or solely aerobic ET interventions (4 animal studies); these 
programs were considered to be within the moderate intensity range.  The length of training 
interventions ranged from 3-15 weeks.  As endpoints, these studies assessed endothelium 
dependent relaxation, PAP and pulmonary vessel wall characteristics pre and post training.  Only 
2 of the 7 human studies found an improvement in pulmonary hemodynamics following ET.  In 
the animal studies, 2 of the 4 demonstrated positive adaptations in pulmonary vessel wall 
characteristics and hemodynamics while the other two demonstrated no improvement.  One 
Winstar rat model study assessed the effects of ET in both a stable and progressive PH cohort.  
While there was a significant improvement in CO and peripheral vascular resistance in the stable 
PH group, there was deterioration in both hemodynamic measures in the progressive PH group. 
From the current body of literature, the effect of ET on pulmonary hemodynamics and vessel 
wall characteristics in humans and animals with PH, from conditions other than LSHD, is 
inconclusive.  There was no deterioration in pulmonary hemodynamics or cardiac function in the 
human trials assessed as well as in the animal trials that included a stable PH arm.  In the one 
trial that included a progressive PH arm, ET induced a detrimental effect.   
Should there be concern for an ET-Induced Deterioration in RV Function in the LSHD – 
PH Phenotype  
 While the effect of ET on left-sided cardiac function has been well investigated, little is 
known about possible effects on the right side of the heart, specifically RV function.  In patients 
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with PH, the rise in PAP during exercise can exceed RV capacity, placing an added strain on an 
already fragile system.
45-47
  The question then becomes, what is the effect of chronic ET on RV 
function in the LSHD – PH phenotype?  This question is unanswerable at this time.  Figure 1 
illustrates a conceptual model in apparently healthy individuals and those with the LSHD – PH 
phenotype; linking differences in the pulmonary vascular response to exercise, the PAP – CO 
relationship, and potential chronic implications for RV function.  In Figure 1, questions remain 
regarding chronic adaptations and function of the RV in both apparently healthy individuals and 
patients with the LSHD – PH phenotype.  A primary issue surrounding the long-term effects of 
ET on RV function in the LSHD – PH phenotype center on the cumulative effect of ET 
intensity/volume.  Research assessing the safety of ET in HF is robust and consistently points to 
moderate aerobic ET and resistance ET, as well as IMT, as being safe and not causing a 
deterioration in left-sided cardiac function.  Given the high prevalence of PH in HF, it is a 
certainty that a number of patients undergoing ET in these trials also suffered from varying 
degrees of elevated PAP.  While not directly assessed in these trials, there is no evidence to 
indicate RV function is compromised with participation in moderate intensity ET, even in the 
LSHD – PH phenotype.  Even so, determination of RV function during moderate intensity ET in 
theLSHD – PH phenotype, particularly with long-term participation, requires confirmation. 
Moreover, there could be a greater concern with a deterioration in RV function for patients with 
the LSHD – PH phenotype that participate in aerobic HIIT, which is gaining increased interest in 
patients with HF.  In fact, there is evidence to convincingly indicate that healthy individuals who 
participate in high volume/intensity ET chronically have a greater likelihood of disproportionate 
and potentially deleterious remodeling of the RV.
48-50
  Thus, it is reasonable to posit there may 
be a chronic ET volume/intensity that may be detrimental to the RV in patients with the LSHD – 
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PH phenotype, particularly given the rise in PAP and strain placed upon the RV in these 
individuals.   
The Clinical Benefits of ET in Patients with LSHD 
 The clinical benefits of ET in LSHD, particularly in patients with HF, is well-
documented and robust.
8, 10, 19, 34, 51
  These well-documented clinical benefits form the basis for 
recommending ET, particularly aerobic and resistance ET, as a standard of care in this 
population.   
 Moderate intensity aerobic ET significantly improves peak VO2, submaximal exercise 
tolerance and quality of life (QoL).
17, 52
  There is evidence to indicate, in select patient cohorts, 
HIIT results a significantly greater improvement in peak VO2 compared to moderate intensity 
aerobic ET,
28
which  also appears to improve prognosis in patients with HF.  Resistance ET 
significantly improves muscle strength and endurance in patients with HF, these are unique and 
added beneficial adaptations that further enhance functional capacity.
34
  Resistance ET also 
significantly improves QoL and peak VO2, the latter of which is a unique benefit to patients 
diagnosed with a chronic disease such a HF.  In patients with inspiratory muscle weakness, IMT 
independently and significantly improves peak VO2 and QoL.
53-55
  While not superior to 
traditional training approaches, NMES has been shown to significantly improve peak VO2, 
muscular strength and endurance, as well as QoL.
39, 56
  The benefits of NMES appears to be 
enhanced in HF patients with advanced disease severity.
42
 
Current ET Recommendations in LSHD 
 Table 1 lists current training recommendations for clinically stable patients with LSHD 
based upon best evidence.  These recommendations were included in a recent publication on 
guidance for ET in patients with chronic obstructive pulmonary disease and PH associated with 
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any pathophysiologic process
57
.  The current body of evidence, assessing the physiologic and 
clinical benefits of ET, as well as safety associated with ET, support the same recommendations 
for patients with LSHD.  These recommendations are also valid for the LSHD – PH phenotype.   
 Current recommendations do indicate moderate intensity aerobic ET performed most if 
not all days of the week is ideal. However, substantial clinical improvements are possible at ET 
volumes below these recommendations.
58
  We are, therefore, continuing to endorse some 
flexibility in this component of ET prescription.  Moderate intensity aerobic ET should be 
viewed as a primary component of the ET program, and for those who are beginning an ET 
regimen from a sedentary status, initiating the aerobic ET component exclusively to build a 
foundation may be preferable.  While evidence for the benefits of aerobic HIIT is compelling, 
more research and clinical work is needed to determine appropriate clinical application.  In 
particular, with respect to the LSHD – PH phenotype, there may be concern over the impact of 
aerobic ET at high intensities on RV function.  As such, we feel continuing to recommend 
moderate intensity continuous aerobic ET, particularly given its well-demonstrated benefit, is 
warranted.  Resistance ET carries unique benefits and should be added to the aerobic ET 
program in all patients.  For those with inspiratory muscle weakness, the addition of IMT would 
be beneficial.  Lastly, for patients with advanced disease severity, who are unable to optimally 
participate in moderate intensity aerobic and resistance ET, utilization of NMES should be 
considered as a bridge/compliment to traditional ET approaches in those patients with advanced 
disease severity and substantial functional deficits.  As a patient in this category improves 
functionally, the NMES component may be weaned as moderate intensity aerobic and resistance 
ET are up-titrated.  
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 It is important to consider compliance and long term adherence with the ET program.  
Most patients with LSHD will begin an ET program from a state of minimal to no physical 
activity.  As such, initiating too high of an ET volume at the onset of an ET program, with 
multiple training components (i.e., aerobic, resistance, IMT simultaneously) , may have a 
detrimental effect on long term adherence.  A pragmatic approach may, therefore, be optimal, 
where components of the ET program are added one at a time, perhaps at a volume below target 
levels.  For example, in a patient with the LSHD– PH phenotype, advanced disease severity, a 
completely sedentary lifestyle and a significantly compromised functional capacity, beginning an 
ET program with moderate intensity aerobic ET only, three times per week, 30 minutes per 
session, may be prudent; ET volume and components can be up-titrated gradually, being mindful 
of the patient’s response to the program. In addition, there is a rapidly growing recognition that 
the patient should be an active participant in his or her plan of care, which includes the 
development and evolution of an ET program.
59
  Taking a conservative and engaging approach 
may help optimize long term ET adherence and success. 
The Need for ET Research in the LSHD – PH Phenotype  
 Research specifically investigating the effect of ET in the LSHD – PH phenotype is 
lacking.  Given the high prevalence of PH in patients with LSHD, particularly those diagnosed 
with HF, investigation into this area is warranted.  Several possible research lines are included 
herein. 
Better elucidating the effect of ET on pulmonary hemodynamics, as well as vessel wall 
characteristics, would be of value.  Studies assessing the acute and chronic effects of ET on RV 
structure and function in patients with the LSHD – PH phenotype would also be of high 
importance, including different training paradigms (e.g., moderate intensity aerobic training vs. 
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HIIT).  Moreover, given the unique pathophysiologic processes associated with HFrEF and 
HFpEF, separate analyses into the unique effects of ET are warranted.   
The optimal approach to treating the LSHD – PH phenotype would be preventing its 
onset completely.  Recently, Wan et al.
60
 described pre-clinical diastolic dysfunction, a 
phenomenon that precedes HF.  In an associated editorial, Pressler et al.
61
 proposed ET as an 
intervention of choice for pre-clinical diastolic dysfunction; the authors of this review echo 
support for consideration of such an approach.  Future research assessing the impact of primary 
prevention ET interventions as a means to reduce the risk of developing HF altogether in patients 
at high risk would be a worthwhile endeavor.  
Conclusions 
 Clearly, ET is now recognized as a valuable medical intervention in virtually all patient 
populations, including those diagnosed with the LSHD – PH phenotype.  Ideally, patients should 
fully participate in a comprehensive ET program, individually tailored to optimally improve 
physiologic function and clinical outcomes.  It is, however, important to recognize that 
―something is better than nothing‖ and a primary goal, particularly at the onset, is to transition 
from a completely sedentary lifestyle to some level of routine physical activity that is sustainable 
over the long-term.  Moderate intensity aerobic ET should be viewed as the primary ET 
intervention in the LSHD – PH phenotype.  Resistance ET and IMT can further enhance 
functional improvements in patients who demonstrate the willingness to be compliant with a 
multi-pronged ET program. Finally, NMES can be a useful tool in more advanced disease. To 
optimize long-term adherence, patients should be engaged as active participants in developing 
and, over time, evolving the ET program.  
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Table 1: Exercise Training Program Recommendations  
Adapted from: Arena R. Exercise testing and training in chronic lung disease and pulmonary arterial hypertension. ProgCardiovasc 
Dis. 2011 May-Jun;53(6):454-63 (Table 3). 
Exercise Training 
Approach 
General Prescription Guidelines Training Modes 
Aerobic: Moderate Intensity  3-7 days/week 
 30-60 minutes/day (accumulated or continuous) 
 50-85% of maximal aerobic capacity 
 Walking/treadmill 
 Lower extremity ergometer 
 Elliptical 
 Combination of above 
Resistance: Moderate 
Intensity 
 2-3 days/week 
 1 set 
 10-15 repetitions per set 
 8-10 exercises; preferably multi-joint (e.g., bench 
press, hip sled, etc.) 
 Alternate upper and lower body exercise  
 Cable weight systems 
 Free weights 
 Bands 
Inspiratory Muscle  1-2 times/day 
 15-30 minutes per session 
 3-7 days/per week 
 ≥30% of maximal inspiratory pressure 
 Handheld, threshold load 
trainer 
Neuromuscular electrical 
stimulation 
 Electrical frequency: 10-50 Hz 
 Pulse duration: 200-700 µseconds 
 On cycle: 2-10 seconds 
 Off cycle: 4-50 seconds 
 Intensity: visibly strong muscle contraction to maximal 
tolerance 
 1-2 times/day 
 30-60 minutes/session 
 3-7 days/week 
 Electrical pads on bilateral quadriceps, calf and 
possibly hamstring muscles 
 Handheld battery operated 
units 
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Figure 1: Comparison between normal and abnormal pulmonary arterial vessel response 
to exercise: implications for cardiac output with an acute exercise stimulus and right 
ventricular function with chronic exercise 
 
 
 
